HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance

Antiviral Therapy

Volumn 17, Issue 2, 2012, Pages 387-394

  Shin, Jung Woo ^a   Jung, Seok Won ^a   Park, Bo Ryung ^a   Kim, Chang Jae ^a   Eum, Jun Bum ^a   Kim, Byung Gyu ^a   Jeong, In Du ^a   Bang, Sung Jo ^a   Park, Neung Hwa ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; LAMIVUDINE; VIRUS DNA;

ADD ON THERAPY; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENCY; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; VIREMIA; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KIDNEY FUNCTION TESTS; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84860342017     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1945     Document Type: Article

References (33)

1. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
2. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
3. Liaw Y F, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172-180. (Pubitemid 30452590)
4. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32:828-834.
5. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722. (Pubitemid 37500436)
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-807. (Pubitemid 36245756)
7. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816. (Pubitemid 36245757)
8. Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101. (Pubitemid 38040727)
9. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81-90. (Pubitemid 38040726)
10. Fung J, Lai CL, Yuen JC, et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther 2007; 12:41-46. (Pubitemid 46340424)
11. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45:307-313. (Pubitemid 46374587)
12. Chen CH, Wang JH, Lee CM, et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther 2006; 11:771-778.
13. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44:283-290. (Pubitemid 43069209)
14. Chan HL, Wong VW, Tse CH, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007; 25:891-898. (Pubitemid 46525336)
15. Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. J Hepatol 2008; 48:923-931.
16. Hosaka T, Suzuki F, Suzuki Y, et al. Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 2007; 42:368-374. (Pubitemid 47097253)
17. Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42:1414-1419. (Pubitemid 43260045)
18. Buti M, Elefsiniotis I, Jardi R, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 2007; 47:366-372. (Pubitemid 47176160)
19. Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46:1695-1703.
20. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-536. (Pubitemid 41096641)
21. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147:745-754. (Pubitemid 351664439)
22. Gallego A, Sheldon J, Garcia-Samaniego J, et al. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008; 15:392-398. (Pubitemid 351473632)
23. Shin J W, Park NH, Jung SW, et al. Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. Antivir Ther 2009; 14:181-186.
24. Kim MC, Jung SW, Shin JW, Park NH. The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. Dig Dis Sci 2011; 56:1215-1221.
25. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133:1445-1451. (Pubitemid 350047463)
26. Vassiliadis T, Nikolaidis N, Giouleme O, et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005; 21:531-537. (Pubitemid 40381504)
27. Kurashige N, Hiramatsu N, Ohkawa K, et al. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol 2009; 44:601-607.
28. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139:1207-1217.
29. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virusmonoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51:73-80.
30. Yuen M F, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34:785-791. (Pubitemid 32928004)
31. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
32. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4:936-962. (Pubitemid 44118844)
33. Kim H, Jee YM, Song BC, et al. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007; 50:52-57. (Pubitemid 46005272)